GLP-1 family
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW, Steen O, Lucas KJ, et al. · Lancet Diabetes Endocrinol · 2024
PMID: 38330987 · DOI: 10.1016/S2213-8587(24)00007-X
Summary
Phase 2 dose-finding randomized, double-blind, placebo-controlled trial of once-weekly subcutaneous survodutide (GLP-1/glucagon dual agonist) at 0.6 to 4.8 mg vs placebo, 46 weeks, in 387 adults with obesity. Primary endpoint: percent change in body weight.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
More GLP-1 family citations
- Once-Weekly Semaglutide in Adults with Overweight or ObesityN Engl J Med · 2021
- Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)Lancet · 2021
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3)JAMA · 2021